肥厚型心肌病家族筛查:系统随访中低产出亲属的识别
该回顾性队列研究纳入丹麦东部2006至2023年筛查的531个家族共1230名亲属,基线临床与基因联合诊断率为26%,平均随访7年额外4%发生HCM。携带可能致病/致病变异及基线左室最大壁厚更大是HCM发生的最强预测因素;基因未明家族中基线MWT≥10 mm为最佳分类阈值。
要点
- 单次筛查诊断率约1/4,7年随访额外检出4%。
- 致病变异携带者与基线MWT更大者HCM风险最高。
- 基因未明家族中基线MWT≥10 mm者需重点随访。
核心结论
- HCM亲属单次筛查诊断率为26%,平均7年随访额外4%发生HCM。
- 携带可能致病/致病变异与基线左室最大壁厚更大是HCM发生的独立预测因素。
- 基因未明家族中基线MWT≥10 mm为预测HCM发生的最佳分类阈值。
研究设计与样本
- 回顾性队列研究,纳入丹麦东部2006至2023年遗传性心肌病门诊筛查的531个家族共1230名亲属。
- 亲属55%为女性,年龄42±17岁。
- 平均随访7年(共6762人年)。
主要发现
- 基线临床与基因联合诊断率为26%(n=321)。
- 随访期间43名(4%)亲属新发HCM。
- 携带可能致病/致病变异者发生HCM的HR为4.58(95%CI 2.50-8.40,P<0.001)。
- 左室最大壁厚每增加1 mm,HCM发生HR为2.21(95%CI 1.76-2.77,P<0.001)。
- 基因未明家族中基线MWT≥10 mm预测HCM发生的AUC为0.80,MWT<10 mm者仅2名(0.4%)随访发生HCM。
关键数值与推荐
- 基因未明家族中基线MWT≥10 mm为预测HCM发生的最佳分类阈值(AUC 0.80)。
临床怎么用
- 对HCM亲属应进行临床与基因联合筛查,单次筛查可检出约1/4受累者。
- 对携带可能致病/致病变异或基线MWT较大的亲属应加强长期随访。
- 基因未明家族中基线MWT≥10 mm的亲属需重点监测HCM发生。
局限性
- 本研究为回顾性队列研究,结果可能受选择偏倚影响。
- 研究人群来自丹麦东部单区域,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disease, and clinical and genetic family screening is recommended by guidelines. OBJECTIVES: This study sought to investigate the diagnostic yield of screening relatives of HCM patients and identify predictive factors for HCM development during long-term follow-up in relatives from gene-elusive families. METHODS: This was a retrospective cohort study of families screened at clinics for inherited cardiomyopathies in Eastern Denmark, from 2006 to 2023. RESULTS: We included 1,230 relatives (55% female; age: 42 ± 17 years) from 531 families. The combined clinical and genetic yield at baseline was 26% (n = 321). After 7 years (mean) of follow-up (6,762 person-years), 43 (4%) additional relatives developed HCM. The strongest predictors of developing HCM were carrying a likely pathogenic/pathogenic variant (HR: 4.58; 95% CI: 2.50-8.40; P < 0.001) and larger left ventricular maximum wall thickness (MWT) (HR: 2.21 per mm; 95% CI: 1.76-2.77 per mm; P < 0.001). In gene-elusive families, we found that an MWT of ≥10 mm represented the optimal classification threshold for developing HCM (area under the curve: 0.80), with only 2 (0.4%) relatives from gene-elusive families with an MWT of <10 mm developing HCM during follow-up. CONCLUSIONS: In HCM, the diagnostic yield of a single screening visit was 1 in 4, and the additional yield during 7 years of follow-up was 4%. Gene carriers and relatives from gene-elusive families with a baseline MWT of ≥10 mm were at the highest risk of developing HCM during follow-up. These findings may inform future recommendations on the management of relatives of HCM patients.
引用
- Silajdzija E, Vissing CR, Christensen EB, et al. Family Screening in Hypertrophic Cardiomyopathy: Identification of Relatives With Low Yield From Systematic Follow-Up. J Am Coll Cardiol. 2024. PMID: 39365224. doi:10.1016/j.jacc.2024.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。